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Summary
Spinal neurofibromatosis (SNF) has been considered to
be an alternative form of neurofibromatosis in which
spinal cord tumors are the main clinical characteristic.
Familial SNF has been reported, elsewhere, in three fam-
ilies—two linked to markers within the gene for neu-
rofibromatosis type 1 (NF1) and the other not linked to
NF1—but no molecular alterations have been described
in these families. We describe a three-generation family
that includes five members affected by SNF. All the af-
fected members presented multiple spinal neurofibromas
and cafe´ au lait spots, one member had cutaneous neu-
rofibromas, and some members had other signs of NF1.
Genetic analysis, performed with markers within and
flanking theNF1 gene, showed segregation with theNF1
locus. Mutation analysis, performed with the protein-
truncation test and SSCP/heteroduplex analysis of the
whole coding region of theNF1 gene, identified a frame-
shift mutation (8042insA) in exon 46, which should re-
sult in a truncated NF1 protein. The 8042insAmutation
was detected in all five family members with the SNF/
NF1 phenotype. To our knowledge, this is the first time
that a mutation in the NF1 gene has been associated
with SNF. The clinical homogeneity in the severity of
the disease among the affected members of the family,
which is unusual in NF1, suggests that a particular prop-
erty of the NF1 mutation described here, a gene closely
linked toNF1, or posttranscriptional events are involved
in this severe neurological phenotype.
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Introduction
The neurofibromatoses are a group of neurocutaneous
syndromes, characterized by growth abnormalities of the
nervous system and of various organs, that show ex-
treme clinical heterogeneity (reviewed in Riccardi 1992).
Attempts to classify the neurofibromatoses have led to
the consideration of two main clinical forms, type 1
(NF1) and type 2 (NF2), as well as several alternate and
related forms (reviewed in Riccardi 1992 and in Vis-
kochil and Carey 1994). Of these, only NF1 and NF2
are well-defined clinical entities for which genes have
been identified (Cawthon et al. 1990; Viskochil et al.
1990; Wallace et al. 1990; Rouleau et al. 1993; Troffater
et al. 1993).
The gene responsible for NF1 maps to chromosome
band 17q11.2, spans 1350 kb of genomic DNA, and
encodes an mRNA, of 11–13 kb, that contains at least
60 exons (Danglot et al. 1995; Li et al. 1995). The gene
product of NF1, neurofibromin, has a central domain
with sequence similarity to the GTPase-activating pro-
tein family, which can down-regulate p21-ras (Ballester
et al. 1990; Martin et al. 1990; Xu et al. 1990a, 1990b).
Moreover, the identification of somatic mutations in the
NF1 gene, from several NF1- and non–NF1-related tu-
mors (Li et al. 1992; Xu et al. 1992; Andersen et al.
1993; Legius et al. 1993; The et al. 1993; Shannon et
al. 1994; Colman et al. 1995; Sawada et al. 1996; Serra
et al. 1997), supports the notion that NF1 is a tumor-
suppressor gene. The NF2 gene, which is also a tumor-
suppressor gene, maps to chromosome 22q12 and en-
codes a 595–amino acid protein, designated “merlin/
schwannomin,” that has a sequence similar to that of a
family of proteins that have been postulated to connect
the cytoskeleton to the cell membrane (Luna and Hitt
1992; Rouleau et al. 1993; Troffater et al. 1993).
Spinal neurofibromatosis (SNF) has been considered
to be an alternative form of neurofibromatosis. The pres-
ence of multiple spinal cord tumors, occurring in several
members of the same family and segregating in an au-
tosomal dominant fashion (familial SNF), has been re-
ported, elsewhere, in three families. For two of these
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Figure 1 Pedigree of a three-generation family with SNF. Segregation of markers flanking and within the NF1 gene are shown (upper
left). Blackened symbols indicate individuals with the NF1/SNF phenotype. The haplotype associated with the disease is boxed.
Table 1
Clinical Features of Family Members Affected with SNF
Feature
Patient
I-2 II-3 II-7 II-8 III-2
Age (years) 58a 34 24 21 12
Spinal neurofibromas C,D,L C,D,L C,D,L D,L C,D
Multiple CLS Present Present Present Present Present
Cutaneous neurofibromas (n) Absent Present (3) Absent Absent Absent
Lisch nodules ND ND ND Present Present
Paraparesis (age [years]) Present (45) Present (23) Absent Absent Absent




. . . . . .
NOTE.—C  cervical; D  dorsal; L  lumbar; CLS  cafe´ au lait spots; and ND  not determined.
a Deceased.
families, linkage to markers within the NF1 gene was
established; for the remaining family, no linkage to NF1
was found (Pulst et al. 1991; Poyhonen et al. 1997). No
molecular alterations have been detected in these
families.
We have analyzed a family that includes five members
severely affected by SNF. Mutation analysis, by means
of protein-truncation testing (PTT), of the NF1 cDNA
allowed the identification of a frameshift mutation that
cosegregates with the disease. This provides further ev-




The family analyzed in this study had five members,
in three generations, affected by SNF (fig. 1 and table
1). The five affected members were informed about the
study, and consent was obtained from all of them. Pa-
tient I-2 was a 58-year-old woman who developed pro-
gressive paraparesis of her legs and right arm when she
was 45 years old. She had multiple cafe´ au lait spots
(CLS) but no cutaneous neurofibromas. Magnetic res-
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Figure 2 Coronal T2-weighted spinal MRI scan of patients II-3 and III-2. A, Patient II-3: multiple bilateral neurofibromas, at cervical
and dorsal levels, with the intra- and extraspinal components of a dumbbell neurofibroma growing into both the brachial plexus and the apical
region of the lung. B, Patient III-2: multiple bilateral, paravertebral tumors, from C2–C3 to D3–D4, and two paravertebral masses, in the right-
and left-lung apical regions. The arrowheads point to some of the spinal neurofibromas.
onance imaging (MRI) of the spine detected multiple
intradural extramedullary masses, in the cervical, dorsal,
and lumbar segments, corresponding to neurofibromas.
Some of these masses had both intradural and extradural
components, the so-called dumbbell tumors, with a large
extraspinal component that produced foraminal enlarge-
ment. A surgical intervention to remove intradural neu-
rofibromas from C1–C4 was performed in 1989. The
patient had a very torpid clinical evolution that culmi-
nated in cardiac insufficiency and subsequent death,
from a myocardial infarction, in 1996. Patient II-3 is a
34-year-old woman who had a surgical operation, when
she was 16 years old, to remove a mediastinal neuro-
fibroma. She has multiple CLS and three cutaneous neu-
rofibromas. When she was 23 years old, this patient
began to have difficulty walking and to show signs of
progressive spastic paraparesis. The spinal MRI exam-
ination showed multiple tumors at C1–C7 (figs. 2A and
3A). A laminectomy was performed to remove neuro-
fibromas from levels C1–C5. Shortly after surgery, the
patient developed a complete transverse medullar syn-
drome, at the C2–C3 level, that required mechanical
ventilation. Patient II-7 is a 24-year-old woman with
multiple CLS and antecedents of surgical resection of a
plexiform neurofibroma on the right arm. The spinal
MRI examination disclosed multiple intra- and extra-
spinal neurofibromas in the cervical region, at the
D6–D7 level, and in the lumbosacral region. Patient II-
8 is a 21-year-old woman with multiple CLS and Lisch
nodules. The MRI scans demonstrated bilateral lung ap-
ical tumors and a left paravertebral mass, at the L5 level.
Patient III-2 is a 12-year-old girl with multiple CLS and
Lisch nodules. The spinal MRI showed multiple bilateral
tumors, from C2–C3 to D3–D4, and two paravertebral
masses in the right- and left-lung apical regions (figs. 2B
and 3B). The physical examination of the other members
of the family revealed none of the major clinical features
of NF1 (cutaneous neurofibromas, Lisch nodules, or
CLS).
RNA/DNA Extraction
Total RNA was extracted, from peripheral blood lym-
phocytes, by use of the Tripure isolation reagent (Boeh-
ringer Mannheim), in accordance with the manufac-
turer’s instructions. DNA was extracted by means of the
“salting out” method (Miller et al. 1988).
Reverse Transcription and PTT Analysis
Two to five micrograms of RNA were reverse tran-
scribed with 500 ng random hexamers and 200 U Su-
perscript II reverse transcriptase (RT [Gibco-BRL]) in a
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Figure 3 Sagittal T2-weighted spinal MRI scan of patients II-3 and III-2. A, Patient II-3: intradural and extramedullary neurofibromas
(arrowheads), with compression of the cervical cord and enlargement of the cervical spinal canal. B, Patient III-3: multiple cervical and dorsal
neurofibromas (arrowheads), with extension outward from the spinal canal through the intervertebral foramen.
20-ml reaction volume, under conditions recommended
by the manufacturer. The entire NF1 cDNA was then
amplified (40 cycles of 1 min at 94C, 1 min at 54C,
and 1 min at 72C), with five pairs of overlapping prim-
ers that incorporate a T7 promoter and translation in-
itiation site, as described elsewhere (Heim et al. 1995).
After in vitro transcription/translation incorporating 35S-
methionine, the samples were electrophoresed on a 12%
SDS-polyacrylamide gel. The gel was then dried and sub-
jected to autoradiography for 6–48 h. When an abnor-
mal fragment was detected, primers flanking the DNA
sequence with the putative mutation were designed, and
the RT-PCR product was sequenced by use of an au-
tomatic genetic analyzer (ABI PRISM 377 DNA
Sequencer).
SSCP/Heteroduplex Analysis
The whole coding region of the NF1 gene, amplified
in 10 overlapping fragments (Hoffmeyer et al. 1994),
was also analyzed by SSCP/heteroduplex analysis, as de-
scribed elsewhere (Sala and Espinosa-Parrilla, in press).
Segregation Analysis
Haplotype analysis for seven NF1 markers (four in-
tragenic and three extragenic) was performed as de-
scribed elsewhere (La´zaro et al. 1993). Haplotype anal-
ysis for four NF2 markers (one intragenic CA-repeat and
three extragenic markers: D22S268, D22S273, and
D22S280) was performed as described elsewhere (Mar-
ineau et al. 1993; Bourn and Strachan 1995). Restric-
tion-enzyme analysis of cDNA, for detection of the
8042insA mutation, was performed as described else-
where (Sambrook et al. 1989).
Results
Five family members affected with NF1 shared a very
severe neurological phenotype that included spinal neu-
rofibromas (fig. 1 and table 1). Two of these five family
members had paraparesis; the other three are still young
(aged 12–24 years). All five members fulfilled the Na-
tional Institutes of Health (NIH) diagnostic criteria for
NF1 (Stumpf et al. 1988). The SNF/NF1 phenotype seg-
regated with a seven-marker haplotype (four NF1 in-
tragenic and three extragenic markers) (fig. 1). NF2
markers (one NF2 intragenic and three extragenic) did
not segregate with the disease (data not shown).
PTT analysis of the fifth segment of the NF1 cDNA
(as indicated by Heim et al. [1995] for PTT analysis)
detected a 55.4-kD polypeptide, in addition to the nor-
mal 68.5-kD product, for the 3′ end of the NF1 cDNA
(exons 35–49) (fig. 4A), which suggests a truncating mu-
tation between nucleotides 8000 and 8100 of the NF1
coding sequence. Sequencing of the RT-PCR product re-
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Figure 4 Identification of mutation 8042insA in the SNF family. A, PTT analysis, showing a truncated polypeptide, of 55.4 kD(*) , in
addition to the normal peptide, of 68.5 kD. The truncated NF1 polypeptide was detected only in the affected patients. B, Partial nucleotide
and amino acid sequences of exon 46, showing mutation 8042insA, which creates a TAA stop codon at the mutation site. C, Detection of
mutation 8042insA, which generates an MseI restriction site, by restriction-enzyme analysis. A 488-bp cDNA fragment was amplified, by use
of primers flanking the mutation, and was then digested with the restriction enzymes MseI and AvaII. This resulted in six fragments, of 170,
132, 92, 49, 23, and 22 bp, in the unaffected members, and in two additional fragments, of 71 bp (asterisk [*]) and 21 bp (not shown), in the
affected individuals.
vealed the insertion of an adenine at position 8042, at
codon 2681, in exon 46 of the NF1 gene (fig. 4B). Mu-
tation 8042insA creates a TAA stop codon at the mu-
tation site, which leads to a truncated NF1 protein. PTT
analysis showed that all affected members of the family
produced the truncated polypeptide caused by mutation
8042insA. The mutation generates an MseI restriction
site, which allows confirmation of the molecular alter-
ation, at the cDNA level, by digestion (fig. 4C). The
presence of the mutation in genomic DNA was also con-
firmed by amplification and digestion with the same en-
zyme (data not shown).
The PTT analysis of the other regions of the NF1 gene
did not reveal additional alterations. To uncover other
potential nucleotide changes that could have escaped the
PTT analysis (missense mutations and in-frame inser-
tions and deletions), we studied the complete coding
region of the NF1 gene of the SNF family, by SSCP/
heteroduplex analysis of 10 overlapping fragments of
the NF1 cDNA, and we found only the mutation
8042insA.
Discussion
Because of the extreme clinical heterogeneity of the
neurofibromatoses, there have been many attempts to
classify these disorders into distinct categories (reviewed
in Riccardi [1992] and in Viskochil and Carey [1994]).
As yet, only NF1 and NF2 have been confirmed as ge-
netically distinct diseases, as a result of the cloning of
the respective genes. There are several related or alter-
nate forms of NF1, such as Watson syndrome (Tassa-
behji et al. 1993; Ahlbom et al. 1995), Noonan syn-
drome (Tassabehji et al. 1993; Bahuau et al. 1996),
autosomal dominant multiple CLS (Brunner et al. 1993;
Abeliovich et al. 1995), and LEOPARD syndrome (Wu
et al. 1996); however, there exists some controversy
about their NF1 molecular basis.
SNF has also been described as an entity that is distinct
from NF1 and in which the main clinical characteristic
is symptomatic spinal cord tumors, which are present in
only 5% of NF1 cases (Huson et al. 1988; Von Deimling
et al. 1995) and are actually more common in NF2.
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Recently, it has been suggested that spinal neurofibromas
associated with NF1 occur more often than initially
thought, since they were found, by spinal MRI, in 36%
of the NF1 patients studied by Poyhonen et al. (1997)
but were associated with clinical symptoms in only 7%
of the patients. The infrequent detection, by other in-
vestigators, of spinal neurofibromas in NF1 patients
could be explained by the lack of routine spinal MRI
studies. Although asymptomatic spinal neurofibromas
are probably more common than previously thought,
the occurrence of multiple spinal neurofibromas in all
the affected members of the same family is exceptional.
To date, only three other SNF families have been stud-
ied at the genetic level. Pulst et al. (1991) described two
families, one of which satisfied NIH NF1 criteria and
showed linkage to the NF1 locus. In the second family,
all the affected members had only spinal cord tumors;
this family was excluded by linkage from 17q11.2 and
is probably linked to NF2 (Pulst et al. 1991, 1997).
Recently, Poyhonen et al. (1997) described a family with
multiple CLS, spinal neurofibromas, and some other
signs of NF1 (dermal neurofibromas and axillary and
inguinal freckles). Linkage to the NF1 locus was estab-
lished, and linkage to the NF2 locus was excluded. No
mutations in either NF1 or NF2 have been described in
any of these families. All the affected members of the
three-generation family we describe here have spinal
neurofibromas, fulfill NIH NF1 criteria, and have the
frameshift mutation 8042insA in the NF1 gene. This
clearly links the NF1 gene with familial SNF.
A hallmark of NF1 is the high phenotypic variability
between affected individuals, even among members of
the same family. The only phenotype-genotype corre-
lation described so far in NF1 concerns the mental re-
tardation and/or learning disabilities, mild facial dys-
morphology, and large number of early-onset cutaneous
neurofibromas associated with large deletions encom-
passing the whole NF1 gene (Kayes et al. 1994; Wu et
al. 1995; Leppig et al. 1996; Upadhyaya et al. 1996; Wu
et al. 1997). One of the striking characteristics of the
family reported here and of the SNF families reported
elsewhere (Pulst et al. 1991; Poyhonen et al. 1997) is
the absence or low number of cutaneous neurofibromas.
This contrasts with the high number of early-onset cu-
taneous neurofibromas seen in patients with deletions of
the whole NF1 gene. The differences between these two
phenotypes could be due to the presence, in the patients
with SNF/NF1, of a partially functional, truncated NF1
protein that is associated with different consequences at
the neurological and dermatological levels.
The NF1 family reported here is unusual because all
the affected members present spinal neurofibromas.
There are various possible explanations for the severe
neurological phenotype in all the affected members of
this family. First, it is possible that the predicted
2,680–amino acid truncated neurofibromin of these pa-
tients has a negative residual function with a special
effect in the development of the neural crest cells that
are responsible for the SNF/NF1 phenotype. However,
we have found a frameshift mutation, in exon 48, that
also gives rise to a stop codon in an NF1 family with a
classical NF1 phenotype and without symptomatic spi-
nal neurofibromas (E. Ars, E. Serra, A. Gaona, J. Garcia,
H. Kruyer, C. La´zaro, X. Estivill, unpublished data).
Second, SNF could be due to a second mutation, either
in the normal NF1 allele or in the same allele that con-
tains mutation 8042insA. However, after an intensive
analysis of the wholeNF1 coding region, we were unable
to detect a second mutation. Furthermore, the second
NF1 allele of four of the patients reported here has been
inherited independently, which excludes the presence of
a common variant involved in the SNF phenotype.
Third, it could be that a mutation in another gene,
closely linked to NF1, is the cause of the SNF in this
family. In support of this, one member of one of the SNF
families described by Pulst et al. (1991) only had mul-
tiple CLS, had no spinal neurofibromas, but had inher-
ited the NF1 haplotype, which suggests that this case
could be recombinant for a linked gene involved in the
development of SNF. These families and others with con-
cordant or discordant clinical data for SNF and NF1
might be useful in the detection of modifier genes for
this SNF/NF1 phenotype. Finally, posttranscriptional
events, such as alternative splicing or editing, that mod-
ulate the expression of the NF1 gene (Skuse and Cap-
pione 1997) could contribute to the development of SNF.
Until now, the molecular genetics of families with spi-
nal cord tumors and with clinical features of neurofi-
bromatosis was unsolved. The identification of the mu-
tation 8042insA in the NF1 gene in the family reported
here strongly suggests that other SNF families that satisfy
NIH NF1 diagnostic criteria might also have mutations
in the NF1 gene. The genetic characterization of these
families should help us to understand the molecular al-
terations that cause this severe neurological phenotype.
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